Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 0.35% and Operating profit at -2.44% over the last 5 years
2
The company has declared Negative results for the last 4 consecutive quarters
3
With ROE of 4.15%, it has a very expensive valuation with a 2.66 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.91%
0%
-22.91%
6 Months
41.61%
0%
41.61%
1 Year
69.72%
0%
69.72%
2 Years
9.34%
0%
9.34%
3 Years
70.76%
0%
70.76%
4 Years
42.59%
0%
42.59%
5 Years
10.03%
0%
10.03%
Beijing Konruns Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.35%
EBIT Growth (5y)
-2.44%
EBIT to Interest (avg)
79.23
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.27
Tax Ratio
48.55%
Dividend Payout Ratio
226.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.40%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
64
Industry P/E
Price to Book Value
2.66
EV to EBIT
58.30
EV to EBITDA
46.15
EV to Capital Employed
3.09
EV to Sales
8.76
PEG Ratio
NA
Dividend Yield
1.14%
ROCE (Latest)
5.30%
ROE (Latest)
4.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
245.60
203.70
20.57%
Operating Profit (PBDIT) excl Other Income
61.30
47.60
28.78%
Interest
1.40
1.40
Exceptional Items
0.50
-0.10
600.00%
Consolidate Net Profit
48.20
40.40
19.31%
Operating Profit Margin (Excl OI)
215.30%
186.20%
2.91%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 20.57% vs -28.30% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 19.31% vs -45.03% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
818.70
914.10
-10.44%
Operating Profit (PBDIT) excl Other Income
154.30
171.70
-10.13%
Interest
6.20
2.80
121.43%
Exceptional Items
-106.00
-32.50
-226.15%
Consolidate Net Profit
21.50
187.60
-88.54%
Operating Profit Margin (Excl OI)
143.30%
139.90%
0.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.44% vs 6.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -88.54% vs 51.41% in Dec 2023
About Beijing Konruns Pharmaceutical Co., Ltd. 
Beijing Konruns Pharmaceutical Co., Ltd.
Retailing
No Details Available.
Company Coordinates 
No Company Details Available






